MFSD2A potentiates gastric cancer response to anti‐PD‐1 immunotherapy by reprogramming the tumor microenvironment to activate T cell response
Cancer Communications2023Vol. 43(10), pp. 1097–1116
Citations Over TimeTop 10% of 2023 papers
Bin Zhang, Chun‐Mei Wang, Hao‐Xiang Wu, Feng Wang, Yangyang Chai, Ye Hu, Bingjing Wang, Yu Zhou, Rong‐Hua Xia, Rui‐Hua Xu, Xuetao Cao
Abstract
MFSD2A potentially serves as a predictive biomarker for anti-PD-1 immunotherapy response in AGC patients. MFSD2A may be a promising therapeutic target to potentiate the efficacy of anti-PD-1 immunotherapy by reprogramming the TME to promote T cells activation.
Related Papers
- → Immunotherapy and tumor microenvironment(2015)303 cited
- → Present and future of cancer immunotherapy: A tumor microenvironmental perspective (Review)(2018)76 cited
- → Nanoparticle-Based Drug Delivery Systems Targeting Tumor Microenvironment for Cancer Immunotherapy Resistance: Current Advances and Applications(2022)71 cited
- → Radiotherapy-induced tumor physical microenvironment remodeling to overcome immunotherapy resistance(2023)39 cited
- → Role of the tumor immune microenvironment in tumor immunotherapy (Review)(2021)41 cited